Dana Chiţu

553 citations

19 papers · 328 indexed · h-index 9

Co-authors: Arjan A. van de Loosdrecht Edo Vellenga Gert J. Ossenkoppele Saskia K. Klein Okke de Weerdt Dimitri Breems Mojca Jongen‐Lavrencic Carlos Graux
Topics: Acute Myeloid Leukemia Research (9 papers)Lymphoma Diagnosis and Treatment (5 papers)Multiple Myeloma Research and Treatments (3 papers)
Cited by: Hematology Genetics Emergency Medicine
Journals: Journal of Clinical Oncology Blood Clinical Cancer Research
Partner nations: Netherlands Belgium Austria

In The Last Decade

Dana Chiţu

17 papers receiving 323 citations

Peers

Countries citing papers authored by Dana Chiţu

Since Specialization

Citations

This map shows the geographic impact of Dana Chiţu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dana Chiţu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dana Chiţu more than expected).

Fields of papers citing papers by Dana Chiţu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dana Chiţu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dana Chiţu. The network helps show where Dana Chiţu may publish in the future.

Co-authorship network of co-authors of Dana Chiţu

This figure shows the co-authorship network connecting the top 25 collaborators of Dana Chiţu. A scholar is included among the top collaborators of Dana Chiţu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dana Chiţu. Dana Chiţu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome 2023 ·BMC Infectious Diseases ·(unknown),(unknown),Peter A. von dem Borne,Nicole M. A. Blijlevens,Dana Chiţu,Martha T. van der Beek,Marta Fiocco,Mark de Boer	2
2	Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)‐mutant myelodysplastic syndromes subtype 2021 ·British Journal of Haematology ·Carolien Duetz,Theresia M. Westers,(unknown),Eline M.P. Cremers,Canan Alhan,(unknown),Heleen Visser-Wisselaar,Dana Chiţu,Aniek O. de Graaf,Linda Smit,Joop H. Jansen,Arjan A. van de Loosdrecht	7
3	Dysplasia andPNH‐type cells in bone marrow aspirates of myelodysplastic syndromes 2021 ·Cytometry Part B Clinical Cytometry ·Theresia M. Westers,Canan Alhan,Heleen Visser-Wisselaar,Dana Chiţu,Arjan A. van de Loosdrecht	1
4	Feasibility, SAR Distribution, and Clinical Outcome upon Reirradiation and Deep Hyperthermia Using the Hypercollar3D in Head and Neck Cancer Patients 2021 ·Cancers ·Michiel Kroesen,(unknown),(unknown),Dana Chiţu,René M. Vernhout,Gerda M. Verduijn,Martine Franckena,José A. Hardillo,Gerard C. van Rhoon,Margarethus M. Paulides	9
5	Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial 2020 ·British Journal of Haematology ·Jeanette K. Doorduijn,Josée M. Zijlstra,Pieternella J. Lugtenburg,(unknown),Lara H. Böhmer,Monique C. Minnema,Marius MacKenzie,(unknown),(unknown),(unknown),Okke de Weerdt,Michel van Gelder,Mels Hoogendoorn,(unknown),Robby E. Kibbelaar,Daphne de Jong,Dana Chiţu,Mars B. vanʼt Veer,Hanneke C. Kluin‐Nelemans	11
6	Machine Learning-Based Flow Cytometry Diagnostics in Myelodysplastic Syndromes: Validation in the HOVON89 Clinical Trial (EudraCT 2008-002195-10) 2020 ·Blood ·Carolien Duetz,Sofie Van Gassen,Theresia M. Westers,(unknown),Eline M.P. Cremers,Canan Alhan,Costa Bachas,(unknown),Heleen Visser-Wisselaar,Dana Chiţu,Aniek O. de Graaf,Joop H. Jansen,Yvan Saeys,Arjan van de Loosdrecht	1
7	Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients 2019 ·Blood ·Gerwin Huls,Dana Chiţu,Violaine Havelange,Mojca Jongen‐Lavrencic,Arjan A. van de Loosdrecht,Bart J. Biemond,Harm Sinnige,(unknown),Carlos Graux,(unknown),Okke de Weerdt,Dimitri Breems,Saskia K. Klein,Jürgen Kuball,Dries Deeren,Wim Terpstra,Marie‐Christiane Vekemans,Gert J. Ossenkoppele,Edo Vellenga,Bob Löwenberg,(unknown)	119
8	Rituximab‐PECC induction followed by ⁹⁰Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study 2019 ·British Journal of Haematology ·Pieternella J. Lugtenburg,Josée M. Zijlstra,Jeanette K. Doorduijn,Lara H. Böhmer,Mels Hoogendoorn,Henriette W Berenschot,Aart Beeker,(unknown),Harry C. Schouten,Yavuz M. Bilgin,Marie José Kersten,Harry R. Koene,A H E Herbers,Daphne de Jong,Nathalie J. Hijmering,King H. Lam,Dana Chiţu,Rolf E. Brouwer,Gustaaf W. van Imhoff,(unknown)	8
9	TCF4 promotes erythroid development 2018 ·Experimental Hematology ·(unknown),(unknown),Davide Monteferrario,(unknown),(unknown),Theresia M. Westers,Dana Chiţu,Gorica Nikoloski,Arjan A. van de Loosdrecht,Bert A. van der Reijden,Joop H. Jansen,Gerwin Huls	6
10	Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study 2018 ·Haematologica ·Natasha K. A. van Eijkelenburg,Mareike Rasche,Essam Ghazaly,Michael Dworzak,Thomas Klingebiel,Claudia Rössig,Guy Leverger,Jan Starý,Eveline S.J.M. de Bont,Dana Chiţu,Yves Bertrand,Benoît Brethon,Brigitte Strahm,Inge M. van der Sluis,Gertjan J.L. Kaspers,Dirk Reinhardt,C. Michel Zwaan	26
11	Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15) 2017 ·Blood ·(unknown),Dana Chiţu,Violaine Havelange,Mojca Jongen‐Lavrencic,(unknown),Bart J. Biemond,(unknown),(unknown),Carlos Graux,(unknown),Okke de Weerdt,Dimitri Breems,Saskia K. Klein,Jürgen Kuball,Gert J. Ossenkoppele,Bob Löwenberg,Edo Vellenga	5
12	First Report on a Successful Screening Program for MYC Rearrangements and a Prospective Clinical Trial Based on MYC Rearrangement in Newly Diagnosed DLBCL Patients in the Netherlands 2017 ·Blood ·Martine E.D. Chamuleau,Marcel Nijland,(unknown),Nathalie J. Hijmering,Dana Chiţu,Josée M. Zijlstra,Otto Visser,Josephine M. I. Vos,Henriette W Berenschot,Rinske Boersma,Marie José Kersten,Daphne de Jong	0
13	Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial 2017 ·Genes Chromosomes and Cancer ·Marian Stevens‐Kroef,Daniël Olde Weghuis,(unknown),Bert van der Reijden,Eline M.P. Cremers,Canan Alhan,Theresia M. Westers,Heleen Visser-Wisselaar,Dana Chiţu,Sónia M. P. R. M. Cunha,Edo Vellenga,Saskia K. Klein,Pierre W. Wijermans,Georgine E. de Greef,M Schaafsma,Petra Muus,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht,Joop H. Jansen	13
14	Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study 2016 ·Clinical Cancer Research ·Annemieke J.M. Nieuweboer,Anne‐Joy M. de Graan,Paul Hamberg,Sander Bins,Robert J. van Soest,Robbert J. van Alphen,Andries M. Bergman,Aart Beeker,Henk van Halteren,Albert J. ten Tije,(unknown),(unknown),Dana Chiţu,Ronald de Wit,Ron H.J. Mathijssen	12
15	Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes 2016 ·Haematologica ·Eline M.P. Cremers,Theresia M. Westers,Canan Alhan,Claudia Cali,Heleen Visser-Wisselaar,Dana Chiţu,Vincent H. J. van der Velden,Jeroen G. te Marvelde,Saskia K. Klein,Petra Muus,Edo Vellenga,(unknown),(unknown),Pierre W. Wijermans,Marian Stevens‐Kroef,(unknown),Joop H. Jansen,Gert J. Ossenkoppele,Arjan A. van de Loosdrecht	44
16	A randomized phase II multicenter trial on the effects of budesonide on cabazitaxel-induced diarrhea: CABARESC. 2016 ·Journal of Clinical Oncology ·Sander Bins,Annemieke J.M. Nieuweboer,Anne‐Joy M. de Graan,Robert J. van Soest,Paul Hamberg,Robbert J. van Alphen,Andries M. Bergman,Aart Beeker,Henk van Halteren,Albert J. ten Tije,Johanna M. Zuetenhorst,(unknown),Dana Chiţu,Ronald de Wit,Ron H.J. Mathijssen,(unknown)	1
17	The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer 2015 ·European Journal of Cancer ·Robert J. van Soest,Annemieke J.M. Nieuweboer,Ellen S. de Morrée,Dana Chiţu,Andries M. Bergman,S.H. Goey,Monique M.E.M. Bos,(unknown),Paul Hamberg,Ronald de Wit,Ron H.J. Mathijssen	47
18	Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study 2015 ·Blood ·Jeanette K. Doorduijn,Monique C. Minnema,Marie José Kersten,Pieternella J. Lugtenburg,Martin R. Schipperus,Marinus van Marwijk Kooy,Marius MacKenzie,Josée M. Zijlstra,Henriette W Berenschot,Martyn Ronald Schaafsma,Dana Chiţu,Hanneke C. Kluin‐Nelemans	15
19	Rituximab-Pecc Induction Followed By 90y-Ibritumomab Tiuxetan Consolidation in Relapsed or Refractory DLBCL Patients Who Are Not Eligible for or Have Failed ASCT: Results from a Phase II HOVON Study 2015 ·Blood ·Pieternella J. Lugtenburg,Josée M. Zijlstra,Jeanette K. Doorduijn,Lara H. Böhmer,Marinus van Marwijk Kooy,Mels Hoogendoorn,Henriette W Berenschot,Aart Beeker,(unknown),Harry C. Schouten,Marleen Luten,(unknown),Dana Chiţu,Rolf E. Brouwer,Gustaaf W. van Imhoff	1

About Dana Chiţu

Dana Chiţu is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine, having authored 19 papers that have together received 328 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (9 papers), Lymphoma Diagnosis and Treatment (5 papers) and Multiple Myeloma Research and Treatments (3 papers). The work is most often cited by research in Hematology (211 citations), Genetics (69 citations) and Emergency Medicine (26 citations). Dana Chiţu has collaborated with scholars based in Netherlands, Belgium and Austria. Frequent co-authors include Arjan A. van de Loosdrecht, Edo Vellenga, Gert J. Ossenkoppele, Saskia K. Klein, Okke de Weerdt, Dimitri Breems, Mojca Jongen‐Lavrencic, Carlos Graux, Harm Sinnige and Bart J. Biemond. Their work appears in journals such as Journal of Clinical Oncology, Blood and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact